Accounting for the Drug Life Cycle and Future Drug Prices in Cost-Effectiveness Analysis
Author:
- 1 January 2011
- journal article
- Published by Springer Nature in PharmacoEconomics
- Vol. 29 (1) , 1-15
Abstract
Economic evaluations of health technologies typically assume constant real drug prices andmodel only the cohort of patients currently eligible for treatment. It has recently been suggested that, in...Keywords
This publication has 9 references indexed in Scilit:
- Whose Costs and Benefits? Why Economic Evaluations Should Simulate Both Prevalent and All Future Incident Patient CohortsMedical Decision Making, 2010
- Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluationHealth Technology Assessment, 2010
- Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Societal Perspective: The ISPOR Drug Cost Task Force Report—Part IIValue in Health, 2010
- The effectiveness and cost-effectiveness of cochlear implants for severe to profound deafness in children and adults: a systematic review and economic modelHealth Technology Assessment, 2009
- Future Drug Prices and Cost-Effectiveness AnalysesPharmacoEconomics, 2008
- The NICE Cost-Effectiveness ThresholdPharmacoEconomics, 2008
- Impact of Generic Drug Entry on Cost-Effectiveness AnalysisMedical Decision Making, 2005
- Taking account of future technology in cost effectiveness analysisBMJ, 2004
- Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug ActThe Journal of Law and Economics, 1992